Literature DB >> 21553239

Recent advances in understanding Crohn's disease.

Antonio Di Sabatino1, Laura Rovedatti, Francesca Vidali, Thomas Thornton Macdonald, Gino Roberto Corazza.   

Abstract

Crohn's disease is a chronic inflammatory bowel disorder resulting from an inappropriate innate and acquired immune response to commensal microorganisms in genetically susceptible individuals. This disease has a fluctuating course, with alternating periods of remission and relapses, and it is characterized by a remarkable clinical heterogeneity; it may be complicated by perianal fistulas, abscesses, and intestinal strictures leading to obstructions, besides several systemic manifestations. However, a complete resolution of the disease is currently not possible, yet Crohn's disease can be managed with established and novel therapies, which achieve long-term remission and acceptable quality of life. This review is focused on novel advances in basic and clinical aspects of Crohn's disease, although it also deals with new trends in diagnosis and treatment.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21553239     DOI: 10.1007/s11739-011-0599-2

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   3.397


  46 in total

1.  Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial.

Authors:  Richard J Farrell; Mazen Alsahli; Yoon-Tae Jeen; Kenneth R Falchuk; Mark A Peppercorn; Pierre Michetti
Journal:  Gastroenterology       Date:  2003-04       Impact factor: 22.682

2.  Inside the microbial and immune labyrinth: totally gutted.

Authors:  Thomas T Macdonald
Journal:  Nat Med       Date:  2010-11       Impact factor: 53.440

3.  The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management.

Authors:  A Dignass; G Van Assche; J O Lindsay; M Lémann; J Söderholm; J F Colombel; S Danese; A D'Hoore; M Gassull; F Gomollón; D W Hommes; P Michetti; C O'Morain; T Oresland; A Windsor; E F Stange; S P L Travis
Journal:  J Crohns Colitis       Date:  2010-01-15       Impact factor: 9.071

4.  Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease.

Authors:  Severine Vermeire; Maja Noman; Gert Van Assche; Filip Baert; Geert D'Haens; Paul Rutgeerts
Journal:  Gut       Date:  2007-01-17       Impact factor: 23.059

Review 5.  Crohn's disease: beyond antagonists of tumour necrosis factor.

Authors:  Laurent Peyrin-Biroulet; Pierre Desreumaux; William J Sandborn; Jean-Frédéric Colombel
Journal:  Lancet       Date:  2008-07-05       Impact factor: 79.321

Review 6.  Disorders of a modern lifestyle: reconciling the epidemiology of inflammatory bowel diseases.

Authors:  Charles N Bernstein; Fergus Shanahan
Journal:  Gut       Date:  2008-05-30       Impact factor: 23.059

Review 7.  Susceptibility genes and overall pathogenesis of inflammatory bowel disease: where do we stand?

Authors:  Claudio Fiocchi
Journal:  Dig Dis       Date:  2009-09-24       Impact factor: 2.404

Review 8.  Mycobacterium avium subspecies paratuberculosis and Crohn's disease: a systematic review and meta-analysis.

Authors:  Martin Feller; Karin Huwiler; Roger Stephan; Ekkehardt Altpeter; Aijing Shang; Hansjakob Furrer; Gaby E Pfyffer; Thomas Jemmi; Andreas Baumgartner; Matthias Egger
Journal:  Lancet Infect Dis       Date:  2007-09       Impact factor: 25.071

Review 9.  Intestinal fibrosis in IBD--a dynamic, multifactorial process.

Authors:  Florian Rieder; Claudio Fiocchi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-04       Impact factor: 46.802

10.  Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial.

Authors:  Stephen B Hanauer; William J Sandborn; Paul Rutgeerts; Richard N Fedorak; Milan Lukas; Donald MacIntosh; Remo Panaccione; Douglas Wolf; Paul Pollack
Journal:  Gastroenterology       Date:  2006-02       Impact factor: 22.682

View more
  7 in total

1.  Iron replacement in inflammatory bowel diseases: an evolving scenario.

Authors:  Fabiana Busti; Giacomo Marchi; Domenico Girelli
Journal:  Intern Emerg Med       Date:  2019-02-05       Impact factor: 3.397

2.  Ultrasonographic findings in Crohn's disease.

Authors:  Gabriella Carnevale Maffè; Laura Brunetti; Pietro Formagnana; Gino Roberto Corazza
Journal:  J Ultrasound       Date:  2014-05-24

3.  Late-Onset Crohn's Disease Is A Subgroup Distinct in Genetic and Behavioral Risk Factors With UC-Like Characteristics.

Authors:  Dalin Li; Talin Haritunians; Carol Landers; Alka A Potdar; Shaohong Yang; Hailiang Huang; L Philip Schumm; Mark Daly; Stephan R Targan; Dermot P B McGovern
Journal:  Inflamm Bowel Dis       Date:  2018-10-12       Impact factor: 5.325

Review 4.  Magnetic resonance enterography in Crohn's disease: How we do it and common imaging findings.

Authors:  Annalisa Mantarro; Paola Scalise; Elisa Guidi; Emanuele Neri
Journal:  World J Radiol       Date:  2017-02-28

5.  The Immunosuppressant Mycophenolic Acid Alters Nucleotide and Lipid Metabolism in an Intestinal Cell Model.

Authors:  Svenja Heischmann; Monika Dzieciatkowska; Kirk Hansen; Dieter Leibfritz; Uwe Christians
Journal:  Sci Rep       Date:  2017-03-22       Impact factor: 4.379

Review 6.  Therapeutic Targeting of Intestinal Fibrosis in Crohn's Disease.

Authors:  Giovanni Santacroce; Marco Vincenzo Lenti; Antonio Di Sabatino
Journal:  Cells       Date:  2022-01-26       Impact factor: 6.600

Review 7.  Stigmatisation and resilience in inflammatory bowel disease.

Authors:  Marco Vincenzo Lenti; Sara Cococcia; Jihane Ghorayeb; Antonio Di Sabatino; Christian P Selinger
Journal:  Intern Emerg Med       Date:  2019-12-31       Impact factor: 3.397

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.